KITE-363: An Autologous Anti-CD19/CD20 CAR-T Product for the Treatment of Neuroinflammatory Autoimmune Diseases (P10-19.004)

Neurology 2026

View at publisher
Authors: Christine Lowe, Brian Kim, Francisco Flores, Jeremy Margaitis, Alessandro Calò, Anna Konecny, Eva Jaghatspanyan, Sean Yoder, Kenneth Ertel, Simone Filosto, Jodi Murakami, David Barrett
DOI: 10.1212/wnl.0000000000213083
Cited by: 1

Abstract

This preclinical study evaluated KITE-363, a dual-targeting anti-CD19/CD20 CAR T-cell therapy in patients with myasthenia gravis (MG) or multiple sclerosis (MS).

Fields of Study & Subjects

CAR-T cell therapy research Monoclonal and Polyclonal Antibodies Research Biomedical Ethics and Regulation

Publication details

Journal / source
Neurology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
106
Issue
11_Supplement_1
Publication date
9 June 2026
Language
EN